Citadel Advisors’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $790K | Buy |
24,900
+11,900
| +92% | +$324K | ﹤0.01% | 8216 |
|
|
2025
Q4 | $353K | Sell |
13,000
-19,300
| -60% | -$508K | ﹤0.01% | 9797 |
|
|
2025
Q3 | $836K | Sell |
32,300
-16,600
| -34% | -$385K | ﹤0.01% | 7936 |
|
|
2025
Q2 | $995K | Buy |
48,900
+15,300
| +46% | +$298K | ﹤0.01% | 7097 |
|
|
2025
Q1 | $610K | Sell |
33,600
-15,400
| -31% | -$344K | ﹤0.01% | 8041 |
|
|
2024
Q4 | $1.24M | Sell |
49,000
-34,900
| -42% | -$948K | ﹤0.01% | 6583 |
|
|
2024
Q3 | $2.85M | Buy |
83,900
+71,700
| +588% | +$2.73M | ﹤0.01% | 4869 |
|
|
2024
Q2 | $452K | Sell |
12,200
-16,400
| -57% | -$619K | ﹤0.01% | 8262 |
|
|
2024
Q1 | $1.2M | Sell |
28,600
-40,900
| -59% | -$1.68M | ﹤0.01% | 6558 |
|
|
2023
Q4 | $2.76M | Sell |
69,500
-3,800
| -5% | -$112K | ﹤0.01% | 4795 |
|
|
2023
Q3 | $2.02M | Buy |
73,300
+54,400
| +288% | +$1.71M | ﹤0.01% | 5191 |
|
|
2023
Q2 | $641K | Sell |
18,900
-2,700
| -13% | -$91K | ﹤0.01% | 7394 |
|
|
2023
Q1 | $777K | Sell |
21,600
-45,600
| -68% | -$1.97M | ﹤0.01% | 7345 |
|
|
2022
Q4 | $3M | Buy |
67,200
+3,600
| +6% | +$129K | ﹤0.01% | 4754 |
|
|
2022
Q3 | $1.79M | Sell |
63,600
-402,400
| -86% | -$12.3M | ﹤0.01% | 5802 |
|
|
2022
Q2 | $12.6M | Buy |
466,000
+315,900
| +210% | +$9.17M | ﹤0.01% | 2386 |
|
|
2022
Q1 | $5.11M | Buy |
150,100
+66,700
| +80% | +$2.13M | ﹤0.01% | 4128 |
|
|
2021
Q4 | $3.22M | Buy |
83,400
+29,500
| +55% | +$1.29M | ﹤0.01% | 5192 |
|
|
2021
Q3 | $2.91M | Buy |
53,900
+31,700
| +143% | +$1.49M | ﹤0.01% | 5438 |
|
|
2021
Q2 | $742K | Sell |
22,200
-51,300
| -70% | -$1.41M | ﹤0.01% | 9122 |
|
|
2021
Q1 | $1.51M | Buy |
73,500
+39,400
| +116% | +$905K | ﹤0.01% | 7075 |
|
|
2020
Q4 | $597K | Sell |
34,100
-76,100
| -69% | -$1.37M | ﹤0.01% | 7820 |
|
|
2020
Q3 | $1.63M | Buy |
110,200
+8,700
| +9% | +$102K | ﹤0.01% | 5103 |
|
|
2020
Q2 | $1.32M | Buy |
101,500
+86,000
| +555% | +$381K | ﹤0.01% | 5320 |
|
|
2020
Q1 | $26K | Sell |
15,500
-3,900
| -20% | -$8.81K | ﹤0.01% | 9231 |
|
|
2019
Q4 | $43K | Buy |
19,400
+6,800
| +54% | +$15.8K | ﹤0.01% | 8793 |
|
|
2019
Q3 | $27K | Sell |
12,600
-700
| -5% | -$1.62K | ﹤0.01% | 8868 |
|
|
2019
Q2 | $36K | Sell |
13,300
-5,800
| -30% | -$19.7K | ﹤0.01% | 8823 |
|
|
2019
Q1 | $94K | Buy |
19,100
+14,680
| +332% | +$77.2K | ﹤0.01% | 8582 |
|
|
2018
Q4 | $13K | Buy |
+4,420
| New | +$21.7K | ﹤0.01% | 8867 |
|
|
2018
Q3 | – | Sell |
-967
| Closed | -$7K | – | 9241 |
|
|
2018
Q2 | $7K | Sell |
967
-606
| -39% | -$8.1K | ﹤0.01% | 8726 |
|
|
2018
Q1 | $55K | Sell |
1,573
-3,367
| -68% | -$130K | ﹤0.01% | 7903 |
|
|
2017
Q4 | $210K | Buy |
4,940
+653
| +15% | +$28K | ﹤0.01% | 7035 |
|
|
2017
Q3 | $184K | Buy |
4,287
+907
| +27% | +$34K | ﹤0.01% | 6758 |
|
|
2017
Q2 | $125K | Buy |
3,380
+1,673
| +98% | +$74K | ﹤0.01% | 6825 |
|
|
2017
Q1 | $92K | Sell |
1,707
-6,986
| -80% | -$364K | ﹤0.01% | 6891 |
|
|
2016
Q4 | $462K | Buy |
8,693
+3,166
| +57% | +$180K | ﹤0.01% | 5023 |
|
|
2016
Q3 | $335K | Sell |
5,527
-1,493
| -21% | -$93K | ﹤0.01% | 5489 |
|
|
2016
Q2 | $462K | Sell |
7,020
-5,213
| -43% | -$331K | ﹤0.01% | 4594 |
|
|
2016
Q1 | $694K | Buy |
12,233
+3,493
| +40% | +$393K | ﹤0.01% | 3951 |
|
|
2015
Q4 | $2.06M | Buy |
8,740
+3,227
| +59% | +$703K | ﹤0.01% | 2703 |
|
|
2015
Q3 | $872K | Sell |
5,513
-854
| -13% | -$242K | ﹤0.01% | 3998 |
|
|
2015
Q2 | $2.41M | Sell |
6,367
-833
| -12% | -$331K | ﹤0.01% | 2842 |
|
|
2015
Q1 | $3.01M | Sell |
7,200
-1,540
| -18% | -$551K | ﹤0.01% | 2586 |
|
|
2014
Q4 | $2.39M | Buy |
8,740
+1,773
| +25% | +$441K | ﹤0.01% | 2702 |
|
|
2014
Q3 | $1.35M | Buy |
6,967
+2,014
| +41% | +$439K | ﹤0.01% | 3325 |
|
|
2014
Q2 | $1.21M | Buy |
4,953
+406
| +9% | +$91.7K | ﹤0.01% | 3253 |
|
|
2014
Q1 | $1.21M | Sell |
4,547
-1,213
| -21% | -$464K | ﹤0.01% | 3205 |
|
|
2013
Q4 | $2.09M | Sell |
5,760
-1,847
| -24% | -$712K | ﹤0.01% | 2509 |
|
|
2013
Q3 | $4.04M | Buy |
7,607
+4,627
| +155% | +$1.59M | 0.01% | 1749 |
|
|
2013
Q2 | $698K | Buy |
+2,980
| New | +$587K | ﹤0.01% | 3513 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Citadel Advisors's CLDX Position: Q1 2026 in Review
Citadel Advisors increased its Celldex Therapeutics (CLDX) stake by 264% in Q1 2026, buying an estimated $3.97M and bringing the position to 200,612 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3953.
Citadel Advisors first reported a position in CLDX in Q2 2013 and has held it in 49 quarters since. The position peaked at $48.1M in Q1 2023. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Citadel Advisors held 200,612 shares of Celldex Therapeutics worth $6.36M as of Q1 2026.
- Citadel Advisors bought 145,511 Celldex Therapeutics shares in Q1 2026, an estimated $3.97M.
- Celldex Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3953 holding.
- Citadel Advisors first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 49 quarters since.
- Citadel Advisors's Celldex Therapeutics position peaked at $48.1M in Q1 2023.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.